ZYXI Stock Overview
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Zynex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.38 |
| 52 Week High | US$17.25 |
| 52 Week Low | US$6.56 |
| Beta | 0.59 |
| 1 Month Change | -29.69% |
| 3 Month Change | -25.61% |
| 1 Year Change | 34.58% |
| 3 Year Change | -48.38% |
| 5 Year Change | 189.02% |
| Change since IPO | 339.06% |
Recent News & Updates
Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?
Mar 30
Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?
Jan 23Recent updates
Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?
Mar 30Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?
Jan 23Short Squeeze Candidate With Low PEG Ratio: Zynex
Oct 05Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system
Sep 21These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely
Aug 02Zynex Cures The Pain Of Its Shareholders: Q2 Results
Aug 01Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain
Jul 25Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?
Jul 12Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance
Jul 11Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?
Apr 13Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly
Mar 23Zynex: Letter Indicates UnitedHealthcare Is Terminating Contract - An Undisclosed Loss Accounting For 50%+ EBITDA
Feb 17Zynex: Turnaround Nears Inevitable End - Largest Payor Cuts TENS Reimbursement, May Eliminate Earnings
Dec 10Zynex: A Fact Finding Mission
Sep 03Zynex Took A Back Seat Due To Covid-19
Aug 22Zynex, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 04What Does Zynex, Inc.'s (NASDAQ:ZYXI) Share Price Indicate?
Mar 09Have Insiders Been Selling Zynex, Inc. (NASDAQ:ZYXI) Shares?
Feb 16Is There More To The Story Than Zynex's (NASDAQ:ZYXI) Earnings Growth?
Feb 02Is Zynex, Inc. (NASDAQ:ZYXI) Popular Amongst Insiders?
Jan 20
Zynex announces filing of patent for sepsis monitor
Jan 14Zynex: Operating Inefficiencies And Gross-To-Net Challenges Place Ceiling On Scalability
Jan 12Zynex announces second utility patent for its blood volume monitor
Jan 06Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?
Jan 05Does Zynex (NASDAQ:ZYXI) Deserve A Spot On Your Watchlist?
Dec 23Is Weakness In Zynex, Inc. (NASDAQ:ZYXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Dec 08Should You Investigate Zynex, Inc. (NASDAQ:ZYXI) At US$13.62?
Nov 24Shareholder Returns
| ZYXI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.8% | -1.2% | 1.0% |
| 1Y | 34.6% | 2.7% | -0.2% |
Return vs Industry: ZYXI exceeded the US Medical Equipment industry which returned 2.7% over the past year.
Return vs Market: ZYXI exceeded the US Market which returned -0.2% over the past year.
Price Volatility
| ZYXI volatility | |
|---|---|
| ZYXI Average Weekly Movement | 14.1% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZYXI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: ZYXI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 900 | Thomas Sandgaard | https://www.zynex.com |
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products.
Zynex, Inc. Fundamentals Summary
| ZYXI fundamental statistics | |
|---|---|
| Market Cap | US$337.84m |
| Earnings (TTM) | US$17.24m |
| Revenue (TTM) | US$169.25m |
19.8x
P/E Ratio2.0x
P/S RatioIs ZYXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYXI income statement (TTM) | |
|---|---|
| Revenue | US$169.25m |
| Cost of Revenue | US$33.99m |
| Gross Profit | US$135.26m |
| Other Expenses | US$118.02m |
| Earnings | US$17.24m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 79.92% |
| Net Profit Margin | 10.19% |
| Debt/Equity Ratio | 14.4% |
How did ZYXI perform over the long term?
See historical performance and comparison